Elon Musk has denied using ketamine recreationally, following a New York Times report detailing concerns from executives at his companies about his alleged drug use. Musk acknowledged having a prescription for ketamine to treat depression, stating it benefits investors, while arguing against its recreational use, and emphasizing his commitment to sobriety and productivity.
Elon Musk has publicly refuted claims of recreational ketamine use, responding to a New York Times report that detailed concerns among executives at his companies regarding his alleged drug consumption. Musk acknowledged possessing a prescription for ketamine to treat depression, framing its use as beneficial to investors, while simultaneously disavowing recreational drug use and emphasizing his dedication to sobriety and productivity. This development directly pertains to "Management & Governance," as the personal conduct and health of a CEO with Musk's influence are significant for corporate stability and investor perception across his ventures. The "Media & Entertainment" theme is also relevant given the public discourse initiated by the media report. The provided signals indicate a neutral sentiment (0.0 score) and a low market impact score (0.05) concerning this news, suggesting a minimal immediate market reaction, potentially because such concerns are already priced in or the market awaits further substantiation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
